bpc-157 clinical trials serbia (Body Protection Compound) | Research Peptide BPC 157 UK: Identity, Evidence

While many of the findings cited above were observed in animal studies (and therefore cannot be extrapolated to humans), there is evidence that researchers are actively exploring BCP-157s potential in these areas

Protocols for neuroprotection use 0.25 to 0.5 mg daily subcutaneously or orally

Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG

Research has documented modulation of nitric oxiderelated processes, reduction of oxidative damage, and suppression of neuroinflammatory responses

Some clinicians and podcasters speak about it as if it were a quietly acknowledged frontier therapy that regulators are sitting on for reasons of patent, profit, or institutional suppression